Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04 2023 - 9:15AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology, will
announce first quarter 2023 financial results on Thursday, May 11,
2023. The Company will host a conference call and live webcast at
4:30 p.m. Eastern Daylight Time on the same day.
Conference call
information:
US/Canada call: (800) 274-8461 / international
call: (203) 518-9783
US/Canada archive: (800) 839-6975 /
international archive: (402) 220-6061
Code for live and archived conference call is
CYCCQ123. Webcast link
For the live and archived webcast, please visit the
Corporate Presentations page on the Cyclacel website
at www.cyclacel.com. The webcast will be archived for 90 days
and the audio replay for 7 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel is a clinical-stage,
biopharmaceutical company developing innovative cancer medicines
based on cell cycle, transcriptional regulation and mitosis
biology. The transcriptional regulation program is evaluating
fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program
plogosertib, a PLK1 inhibitor, in patients with both solid tumors
and hematological malignancies. Cyclacel’s strategy is to build a
diversified biopharmaceutical business based on a pipeline of novel
drug candidates addressing oncology and hematology indications. For
additional information, please visit www.cyclacel.com.
Contacts
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Grace Kim, IR@cyclacel.com |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All
Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2023 to Apr 2024